- Home
- IMAB vs HLVX Comparison
IMAB vs HLVX Comparison
Compare IMAB & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- HLVX
- Stock Information
- Founded
- IMAB 2014
- HLVX 2020
- Country
- IMAB United States
- HLVX United States
- Employees
- IMAB N/A
- HLVX N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- HLVX Health Care
- Exchange
- IMAB Nasdaq
- HLVX Nasdaq
- Market Cap
- IMAB 73.9M
- HLVX 83.7M
- IPO Year
- IMAB 2020
- HLVX 2022
- Fundamental
- Price
- IMAB $2.50
- HLVX $1.86
- Analyst Decision
- IMAB Strong Buy
- HLVX Hold
- Analyst Count
- IMAB 2
- HLVX 5
- Target Price
- IMAB $5.50
- HLVX $2.33
- AVG Volume (30 Days)
- IMAB 1.0M
- HLVX 204.2K
- Earning Date
- IMAB 05-15-2025
- HLVX 08-07-2025
- Dividend Yield
- IMAB N/A
- HLVX N/A
- EPS Growth
- IMAB N/A
- HLVX N/A
- EPS
- IMAB N/A
- HLVX N/A
- Revenue
- IMAB N/A
- HLVX N/A
- Revenue This Year
- IMAB N/A
- HLVX N/A
- Revenue Next Year
- IMAB N/A
- HLVX N/A
- P/E Ratio
- IMAB N/A
- HLVX N/A
- Revenue Growth
- IMAB N/A
- HLVX N/A
- 52 Week Low
- IMAB $0.60
- HLVX $1.34
- 52 Week High
- IMAB $3.08
- HLVX $15.25
- Technical
- Relative Strength Index (RSI)
- IMAB 67.42
- HLVX 52.21
- Support Level
- IMAB $2.29
- HLVX $1.82
- Resistance Level
- IMAB $2.69
- HLVX $2.07
- Average True Range (ATR)
- IMAB 0.35
- HLVX 0.07
- MACD
- IMAB 0.00
- HLVX -0.01
- Stochastic Oscillator
- IMAB 64.53
- HLVX 41.18
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.